News | April 14, 2026
Roche wins CE mark for blood-based MS brain damage test
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Highlights Mirvetuximab-based regimen promise
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours
Paves the way for next-gen ultra-precise gas sensing
Scientists at the forum warned of an increasingly volatile health landscape
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Subscribe To Our Newsletter & Stay Updated
